Why the study?
Physical activity has shown potential for reducing chemotherapy-related cardiotoxicity and enhancing cardiorespiratory function, but its effects in various cancer survivors receiving chemotherapy needed systematic assessment.
Does physical activity improve cardiorespiratory function and reduce cardiotoxicity in cancer survivors undergoing chemotherapy?
Does physical activity improve cardiorespiratory function and reduce cardiotoxicity in cancer survivors undergoing chemotherapy?
Physical activity during chemotherapy improves cardiorespiratory function in cancer survivors but does not significantly improve echocardiographic measures of cardiotoxicity such as LVEF or global longitudinal strain.
Supports integrating physical activity into chemotherapy regimens to reduce cardiotoxicity and improve fitness; strengthens evidence for exercise in cardio-oncology.
Introduction: Physical activity, as a promising complementary therapy, has shown considerable potential for reducing chemotherapy-related cardiotoxicity (CTRCT) and enhancing cardiorespiratory function (CRF). This study aimed to systematically assess the effects of physical activity on CTRCT and CRF in various cancer survivors receiving chemotherapy. Methods: A systematic review and meta-analysis was conducted. A literature search was conducted across 8 databases from inception to January 2024 and was limited to the English and Chinese languages. Statistical analysis was conducted using RevMan 5.3 and Stata 17.0 software. Results: Sixteen randomized controlled trials (RCTs) were included in the systematic review and 15 RCTs were included in the meta-analysis. Among various cancer survivors undergoing chemotherapy, physical activity markedly increased absolute oxygen uptake (VO2peak or VO2max; WMD = 292.99, 95% confidence interval [CI]:87.87 to 498.12, P = .005), with significant effects of subgroup analysis at 4 to 10 weeks ( P = .02) or over 16 weeks ( P < .01), moderate-to-high or high intensity training (both P < .0001), patients with breast cancer ( P = .009) and reported CTRCT ( P = .007); relative VO2peak or VO2max(WMD = 3.30, 95%CI: 2.02 to 4.58, P < .00001), with significant effects of subgroup analysis at 10 to 16 weeks or over 16 weeks, moderate-to-high or high intensity training, patients with breast cancer, with or without reported CTRCT and exercise during chemotherapy (all P < .01); E/A values (WMD = 0.11, 95%CI:0.03 to 0.18, P = .007) and flow-mediated dilatation (WMD = 2.71, 95%CI:1.49 to 3.94, P < .0001). Compared to the control group, physical activity had no significant improvement in E/e’ values ( P = .50), NT-proBNP ( P = .12), hs-cTn ( P = 3.83), left ventricular ejection fraction (WMD = 2.89, 95%CI: −3.28 to 9.06, P = .36) with non-significant effects being independent of exercise intensity or duration, with or without CTRCT and cancer types (all P > .05), and global longitudinal strain (WMD = 0.37, 95%CI: −0.20 to 0.94, P = .20) with non-significant effects being independent of exercise duration and cancer types(both P > .05). Conclusions: Physical activity may be an effective complementary therapy to improve CRF and CTRCT in various cancer survivors, particularly during medium to long duration and moderate-to-high and high intensity exercise with concurrent chemotherapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: